Pancreatic, lung, MTAP-deleted cancers
TNGXTango TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Vopimetostat (TNG462) in Pancreatic, lung, MTAP-deleted cancers. The expected timing is based on the latest available company guidance and may change.
11/6/24- Positive Ph1/2 data. 6/27/25- First patient dosed. 10/23/25- Positive data reported. Combination studies ongoing with add'l data in 2026. 11/04/25:- Updated Ph1/2 data show strong efficacy, favorable safety. Combo and lung updates, pivotal 2L pancreatic trial expected 2026. 03/05/26:- 2026 initial combo Ph1/2 data, lung monotherapy update, and 2L pancreatic pivotal study start expected. 05/13/26:- 2026 Ph1/2 combo data, lung monotherapy update reiterated; ERAS-0015 combo trial initiation planned for H2 2026. 06/08/26:- Initial Ph1/2 combo data positive. Phase 3 trial design, lung mono, and additional combo data planned H2 2026. 08/11/26:- Positive combo data; ESMO October 2026; Ph3 design, lung data, ERAS combo start H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.